What is the typical Tirzepatide dosage?

Published protocols describe 2.5–15 mg weekly, given subcutaneous. This is context from the literature, not a recommendation: a licensed provider sets the dose.

What are the side effects of Tirzepatide?

Risks noted for Tirzepatide include nausea, vomiting, diarrhea, and constipation. Tell your provider about your medications and conditions before starting.

What is the half-life of Tirzepatide?

The reported half-life is ~5 days. Onset is typically reported at 1–4 weeks for appetite reduction.

How should Tirzepatide be stored?

Refrigerated (2–8 °C); use within the pharmacy beyond-use date.

GLP-1 · PEPTIDE

What is Tirzepatide?

Medically reviewed by the G1 Peptides clinical team · Updated October 1, 2026

THE SHORT ANSWER

Tirzepatide is a once-weekly injectable that activates two gut-hormone receptors, GIP and GLP-1. It is approved for type 2 diabetes and for chronic weight management, and in trials produced greater average weight loss than GLP-1 agonists alone.

Tirzepatide at a glance

Type: Peptide
Also known as: Mounjaro, Zepbound
Mechanism: Dual GIP / GLP-1 receptor agonist
Status: FDA-approved
Half-life: ~5 days
Route: Subcutaneous
Dosing range in the literature: 2.5–15 mg weekly
Onset: 1–4 weeks for appetite reduction
Storage: Refrigerated (2–8 °C); use within the pharmacy beyond-use date

How Tirzepatide works

It is a single molecule that activates both the GIP and GLP-1 receptors. Together these increase insulin release when glucose is high, slow stomach emptying and reduce appetite. The dose is raised in steps over several months to limit stomach side effects.

What Tirzepatide is studied for

Weight management
Type 2 diabetes
Appetite control

In the SURMOUNT-1 trial, adults with obesity lost about 21% of body weight on average at the highest dose over 72 weeks. It has also been compared directly with semaglutide in diabetes and in obesity.

Being studied for something is not proof that it works. Results in individuals vary.

Tirzepatide dosing

Published protocols describe 2.5–15 mg weekly, once weekly, given subcutaneous. Onset is typically reported at 1–4 weeks for appetite reduction.

These figures are context from the literature, not instructions. A licensed provider sets the dose and schedule for each patient.

Tirzepatide dosage calculator →

Tirzepatide side effects and risks

Nausea
Vomiting
Diarrhea
Constipation

Tell your provider about every medication and condition before starting, and report anything unexpected. See peptide side effects and safety and who should not use peptides.

Is Tirzepatide FDA approved?

FDA-approved as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management.

Approval and trial status change. This page was last reviewed on October 1, 2026.

Tirzepatide at G1 Peptides

G1 Peptides does not currently supply Tirzepatide. A provider can discuss alternatives in a free consultation.

Tirzepatide questions

What is Tirzepatide?: Tirzepatide is a once-weekly injectable that activates two gut-hormone receptors, GIP and GLP-1. It is approved for type 2 diabetes and for chronic weight management, and in trials produced greater average weight loss than GLP-1 agonists alone.
What is Tirzepatide used for?: Tirzepatide is studied for weight management, type 2 diabetes, and appetite control. In the SURMOUNT-1 trial, adults with obesity lost about 21% of body weight on average at the highest dose over 72 weeks. It has also been compared directly with semaglutide in diabetes and in obesity.
How does Tirzepatide work?: It is a single molecule that activates both the GIP and GLP-1 receptors. Together these increase insulin release when glucose is high, slow stomach emptying and reduce appetite. The dose is raised in steps over several months to limit stomach side effects.
Is Tirzepatide FDA approved?: FDA-approved as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management.
What is the typical Tirzepatide dosage?: Published protocols describe 2.5–15 mg weekly, given subcutaneous. This is context from the literature, not a recommendation: a licensed provider sets the dose.
What are the side effects of Tirzepatide?: Risks noted for Tirzepatide include nausea, vomiting, diarrhea, and constipation. Tell your provider about your medications and conditions before starting.
What is the half-life of Tirzepatide?: The reported half-life is ~5 days. Onset is typically reported at 1–4 weeks for appetite reduction.
How should Tirzepatide be stored?: Refrigerated (2–8 °C); use within the pharmacy beyond-use date.

For educational purposes only, and not medical advice. These statements have not been evaluated by the FDA. Nothing on this page is intended to diagnose, treat, cure, or prevent any disease. Use any compound only under the guidance of a licensed provider.